2017
Oral treatment with foralumab, a fully human anti-CD3 monoclonal antibody, prevents skin xenograft rejection in humanized mice
Ogura M, Deng S, Preston-Hurlburt P, Ogura H, Shailubhai K, Kuhn C, Weiner HL, Herold KC. Oral treatment with foralumab, a fully human anti-CD3 monoclonal antibody, prevents skin xenograft rejection in humanized mice. Clinical Immunology 2017, 183: 240-246. PMID: 28739191, DOI: 10.1016/j.clim.2017.07.005.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, OralAnimalsAntibodies, MonoclonalCD3 ComplexCell ProliferationGraft RejectionHumansMiceSkin TransplantationT-LymphocytesConceptsSkin xenograft rejectionOral treatmentXenograft rejectionT cellsAnti-CD3 monoclonal antibodyConsecutive daily dosesPeripheral T cellsActivation of splenocytesHuman immune systemSplenic CD8Graft acceptanceWeekly dosingIL-10Serum levelsImmune therapySmall bowelHumanized miceDaily dosesImmune modulationMucosal barrierIntragastric doseOral administrationSkin graftsProliferative responseLymphoid cellsβ Cells that Resist Immunological Attack Develop during Progression of Autoimmune Diabetes in NOD Mice
Rui J, Deng S, Arazi A, Perdigoto AL, Liu Z, Herold KC. β Cells that Resist Immunological Attack Develop during Progression of Autoimmune Diabetes in NOD Mice. Cell Metabolism 2017, 25: 727-738. PMID: 28190773, PMCID: PMC5342930, DOI: 10.1016/j.cmet.2017.01.005.Peer-Reviewed Original ResearchConceptsΒ-cellsImmune attackNon-obese diabetic (NOD) miceImmune inhibitory markersProgression of T1DChronic autoimmune diseaseType 1 diabetesLong-term survivalNormal β-cellsHuman β-cellsIslet infiltratesAutoimmune diabetesNOD miceDiabetic miceAutoimmune diseasesInhibitory markersImmune cellsImmune responseDiabetesStemness genesΒ cell identity genesSimilar changesCell deathDiseaseMice
2015
A Preclinical Consortium Approach for Assessing the Efficacy of Combined Anti-CD3 Plus IL-1 Blockade in Reversing New-Onset Autoimmune Diabetes in NOD Mice
Gill RG, Pagni PP, Kupfer T, Wasserfall CH, Deng S, Posgai A, Manenkova Y, Hani A, Straub L, Bernstein P, Atkinson MA, Herold KC, von Herrath M, Staeva T, Ehlers MR, Nepom GT. A Preclinical Consortium Approach for Assessing the Efficacy of Combined Anti-CD3 Plus IL-1 Blockade in Reversing New-Onset Autoimmune Diabetes in NOD Mice. Diabetes 2015, 65: 1310-1316. PMID: 26718498, PMCID: PMC5860426, DOI: 10.2337/db15-0492.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntibodies, MonoclonalAutoimmune DiseasesBiomedical ResearchCD3 ComplexDiabetes Mellitus, Type 1Drug Administration ScheduleDrug Therapy, CombinationFemaleImmunoglobulin Fab FragmentsImmunotherapyInsulinInsulin SecretionInsulin-Secreting CellsInterleukin-1 Receptor Accessory ProteinInterleukin-1betaMice, Inbred NODMulticenter Studies as TopicPilot ProjectsReceptors, Interleukin-1 Type IRecombinant Fusion ProteinsReproducibility of ResultsResearch DesignSpecific Pathogen-Free OrganismsUnited StatesConceptsNew-onset diseaseIL-1 blockadeAnti-CD3 treatmentNOD micePreclinical studiesInterleukin-1IL-1β monoclonal antibodyIslet β-cell massNOD mouse modelImmune Tolerance NetworkType 1 diabetesΒ-cell massApplicable immunotherapiesFuture clinical useStudy entryProspective studyClinical trialsMouse modelMulticenter consortiumAnimal modelsCandidate therapeuticsClinical useTherapeutic agentsMonoclonal antibodiesDisease
2014
Humanized Mice as a Model for Aberrant Responses in Human T Cell Immunotherapy
Vudattu NK, Waldron-Lynch F, Truman LA, Deng S, Preston-Hurlburt P, Torres R, Raycroft MT, Mamula MJ, Herold KC. Humanized Mice as a Model for Aberrant Responses in Human T Cell Immunotherapy. The Journal Of Immunology 2014, 193: 587-596. PMID: 24943216, PMCID: PMC4123131, DOI: 10.4049/jimmunol.1302455.Peer-Reviewed Original ResearchMeSH KeywordsAdrenal GlandsAnimalsAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAutoimmune DiseasesCytokinesDisease Models, AnimalFlow CytometryHumansInterleukin Receptor Common gamma SubunitIpilimumabLiverLymphocyte ActivationMacrophagesMiceMice, Inbred NODMice, KnockoutMice, SCIDPhosphorylationSTAT5 Transcription FactorStem Cell TransplantationSurvival AnalysisT-LymphocytesT-Lymphocytes, RegulatoryTransplantation, HeterologousWeight LossConceptsAnti-nuclear AbsAutoimmune diseasesRegulatory cellsHumanized miceT cellsImmune responseWeight lossMesenteric lymph nodesHuman autoimmune diseasesInduction of autoimmunityT-cell immunotherapyRelease of IFNHuman immune responseImmune-deficient miceIpilimumab treatmentInflammatory sequelaeLymph nodesCell immunotherapyIP-10Macrophage infiltrationCytokine productionSpleen cellsPathologic processesHepatitisMice
2013
Transplant Tolerance to Pancreatic Islets Is Initiated in the Graft and Sustained in the Spleen
Gagliani N, Jofra T, Valle A, Stabilini A, Morsiani C, Gregori S, Deng S, Rothstein DM, Atkinson M, Kamanaka M, Flavell RA, Roncarolo MG, Battaglia M. Transplant Tolerance to Pancreatic Islets Is Initiated in the Graft and Sustained in the Spleen. American Journal Of Transplantation 2013, 13: 1963-1975. PMID: 23834659, PMCID: PMC3869180, DOI: 10.1111/ajt.12333.Peer-Reviewed Original ResearchMeSH KeywordsAdoptive TransferAnimalsAntibodies, MonoclonalCD4 AntigensCD4-Positive T-LymphocytesForkhead Transcription FactorsGraft SurvivalIslets of LangerhansIslets of Langerhans TransplantationLeukocyte Common AntigensMiceMice, Inbred BALB CMice, Inbred C57BLSpleenT-Lymphocytes, RegulatoryTransplantation ToleranceTransplantation, HomologousConceptsTr1 cellsLong-term toleranceTransplant toleranceRegulatory type 1 (Tr1) cellsSpecific immunomodulatory treatmentTreg cell transferCD25- T cellsRegulatory cell typesType 1 cellsAllograft toleranceImmunomodulatory treatmentTreg cellsAllogeneic transplantationT cellsMouse modelImmune systemTregsPancreatic isletsSpleenAllograftsCell typesCellsRegulatory functionsTransplantationEngraftment
2008
Anti‐CD20 Treatment Prolongs Syngeneic Islet Graft Survival and Delays the Onset of Recurrent Autoimmune Diabetes
Hu C, Deng S, Wong FS, Wen L. Anti‐CD20 Treatment Prolongs Syngeneic Islet Graft Survival and Delays the Onset of Recurrent Autoimmune Diabetes. Annals Of The New York Academy Of Sciences 2008, 1150: 217-219. PMID: 19120299, DOI: 10.1196/annals.1447.032.Peer-Reviewed Original ResearchConceptsImmunosuppressive drug treatmentType 1 diabetesIslet transplantationDrug treatmentLong-term immunosuppressive drug treatmentSyngeneic islet graft survivalB cell depletion therapyT cell-mediated destructionAccepted therapeutic optionB-cell depletionPancreatic islet beta cellsCell-mediated destructionIslet graft survivalSyngeneic islet transplantationPancreatic islet transplantationIslet beta cellsRecurrent AutoimmuneTolerance establishmentGraft survivalNOD miceTherapeutic optionsAutoimmune diseasesCell depletionInsulin treatmentBeta cells
2006
Antigen Exposure during Enhanced CTLA-4 Expression Promotes Allograft Tolerance In Vivo
Salvalaggio PR, Camirand G, Ariyan CE, Deng S, Rogozinski L, Basadonna GP, Rothstein DM. Antigen Exposure during Enhanced CTLA-4 Expression Promotes Allograft Tolerance In Vivo. The Journal Of Immunology 2006, 176: 2292-2298. PMID: 16455985, DOI: 10.4049/jimmunol.176.4.2292.Peer-Reviewed Original ResearchConceptsCTLA-4 expressionLong-term engraftmentBALB/cCTLA-4Allograft toleranceCD4 cellsAnti-CD45RB treatmentAcute rejectionCD25 depletionDonor AgUnrelated alloantigensPeritransplant periodAntigen exposureEffector cellsPoor outcomeUnrelated AgAg exposureTransplantationEngraftmentDay 17Day 0Therapeutic enhancementMiceAlloantigensTemporal relationship
2003
Cutting Edge: Transplantation Tolerance through Enhanced CTLA-4 Expression
Ariyan C, Salvalaggio P, Fecteau S, Deng S, Rogozinski L, Mandelbrot D, Sharpe A, Sayegh MH, Basadonna GP, Rothstein DM. Cutting Edge: Transplantation Tolerance through Enhanced CTLA-4 Expression. The Journal Of Immunology 2003, 171: 5673-5677. PMID: 14634073, DOI: 10.4049/jimmunol.171.11.5673.Peer-Reviewed Original ResearchMeSH KeywordsAbataceptAdjuvants, ImmunologicAnimalsAntibodies, MonoclonalAntigens, CDAntigens, DifferentiationCTLA-4 AntigenGraft Enhancement, ImmunologicGraft SurvivalImmunoconjugatesInjections, IntraperitonealInjections, IntravenousIslets of Langerhans TransplantationLeukocyte Common AntigensMaleMiceMice, Inbred BALB CMice, Inbred C57BLMice, KnockoutSignal TransductionTransplantation ToleranceUp-RegulationConceptsCTLA-4 expressionCTLA-4Allograft survivalCTLA4-IgAnti-CD45RB therapyIslet allograft survivalCTLA-4 interactionWild-type miceLong-term engraftmentPeripheral toleranceTransplantation toleranceAllogeneic cellsB7-1B7-2Requisite roleEngraftmentMiceB7SurvivalSpecific roleCritical roleExpressionTransplantationTherapyRecipients
2001
Targeting Signal 1 Through CD45RB Synergizes with CD40 Ligand Blockade and Promotes Long Term Engraftment and Tolerance in Stringent Transplant Models
Rothstein D, Livak M, Kishimoto K, Ariyan C, Qian H, Fecteau S, Sho M, Deng S, Zheng X, Sayegh M, Basadonna G. Targeting Signal 1 Through CD45RB Synergizes with CD40 Ligand Blockade and Promotes Long Term Engraftment and Tolerance in Stringent Transplant Models. The Journal Of Immunology 2001, 166: 322-329. PMID: 11123308, DOI: 10.4049/jimmunol.166.1.322.Peer-Reviewed Original ResearchMeSH KeywordsAdjuvants, ImmunologicAnimalsAntibodies, BlockingAntibodies, MonoclonalB-LymphocytesCD40 LigandCD8-Positive T-LymphocytesCell MovementCytokinesDrug Therapy, CombinationGraft SurvivalIslets of Langerhans TransplantationLeukocyte Common AntigensMaleMiceMice, Inbred BALB CMice, Inbred C57BLModels, ImmunologicalMonocytesProtein IsoformsSignal TransductionSkin TransplantationTransplantation ToleranceConceptsCostimulatory blockadeCD40 ligand blockadeStringent transplant modelSkin allograft survivalBlockade of CD28Induction of toleranceTh2 cytokine expressionLong-term engraftmentImmunogenic allograftAllograft survivalAllograft toleranceAllograft rejectionC57BL/6 recipientsCD8 cellsIslet allograftsTh1 cytokinesTransplant modelCostimulatory pathwayCytokine expressionCD40 ligandMurine modelB cellsTerm engraftmentBlockadeEngraftment